1.06%
-6.92%
-7.14%
-27.11%
-25.82%
-36.13%
-8.51%
AI Spotlight on GMAB
Company Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.
The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease.In addition, it has approximately 20 active pre-clinical programs.The company has a commercial license and collaboration agreement with Seagen Inc.
to co-develop tisotumab vedotin.It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Market Data
| Last Price | 1425 |
| Change Percentage | 1.06% |
| Open | 1420.5 |
| Previous Close | 1410 |
| Market Cap ( Millions) | 90522 |
| Volume | 56437 |
| Year High | 2171 |
| Year Low | 1357.5 |
| M A 50 | 1508.62 |
| M A 200 | 1717.2 |
Financial Ratios
| FCF Yield | 7.25% |
| Dividend Yield | 0.00% |
| ROE | 14.61% |
| Debt / Equity | 3.09% |
| Net Debt / EBIDTA | -80.53% |
| Price To Book | 2.83 |
| Price Earnings Ratio | 19.5 |
| Price To FCF | 13.8 |
| Price To sales | 4.58 |
| EV / EBITDA | 12.81 |
News
- Jan -23 - Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Jan -23 - Is Genmab (GMAB) the High Growth International Stock to Invest in Now?
- Jan -22 - Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
- Jan -16 - GMAB vs. QGEN: Which Stock Is the Better Value Option?
- Jan -14 - Genmab (GMAB) Upgraded to Buy: Here's What You Should Know
- Jan -07 - High Growth Tech Stocks To Watch In January 2025
- Jan -03 - Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -11 - Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
- Dec -09 - Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- Dec -09 - Exploring None's High Growth Tech Stocks With Strong Potential
- Dec -08 - Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
- Dec -08 - Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
- Dec -03 - Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Dec -03 - Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
- Dec -02 - Why Is Genmab A/S (GMAB) Among the Best High Growth Healthcare Stocks to Invest In Now?
- Nov -27 - Why Is Genmab A/S (GMAB) Among the Worst Performing Healthcare Stocks in 2024?
- Nov -25 - Genmab to Present at Citi’s Global Healthcare Conference
- Nov -21 - Why Is Genmab A/S (GMAB) Among the Worst Performing Biotech Stocks in 2024?
- Nov -21 - Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Nov -15 - Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Antibody Therapeutics
Expected Growth : 9.27 %
What the company do ?
Antibody Therapeutics from Genmab A/S are monoclonal antibodies designed to target specific cells or proteins, treating various diseases, including cancer and autoimmune disorders.
Why we expect these perspectives ?
Genmab A/S's Antibody Therapeutics growth is driven by increasing demand for cancer treatments, strategic partnerships, and a strong pipeline of novel antibodies. The company's proprietary DuoBody technology and bispecific antibody capabilities also contribute to its growth, as well as the expansion into new therapeutic areas and geographic markets.
Genmab A/S Products
| Product Range | What is it ? |
|---|---|
| DARZALEX (daratumumab) | A CD38-directed antibody indicated for the treatment of patients with multiple myeloma |
| TECENTRIQ (atezolizumab) | A monoclonal antibody designed to bind with PD-L1, blocking its interaction with PD-1 and B7.1 receptors |
| Kadcyla (trastuzumab emtansine) | An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized anti-HER2 antibody, linked to a cytotoxic agent, DM1 |
| Ofatumumab | A fully human monoclonal antibody that targets CD20, a protein found on the surface of B cells |
Genmab A/S's Porter Forces
Threat Of Substitutes
Genmab A/S operates in the biotechnology industry, which is characterized by high research and development costs. This makes it difficult for substitutes to emerge, as they would need to invest heavily in R&D to develop comparable products.
Bargaining Power Of Customers
Genmab A/S's customers are primarily pharmaceutical companies, which have limited bargaining power due to the company's specialized products and services.
Bargaining Power Of Suppliers
Genmab A/S relies on a few key suppliers for raw materials and services, which gives them some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant R&D investments and regulatory hurdles. This makes it difficult for new entrants to compete with established companies like Genmab A/S.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players competing for market share. Genmab A/S faces intense rivalry from companies like Novo Nordisk and Lundbeck.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 2.38% |
| Debt Cost | 4.54% |
| Equity Weight | 97.62% |
| Equity Cost | 7.90% |
| WACC | 7.82% |
| Leverage | 2.44% |
Genmab A/S : Quality Control
Genmab A/S passed 8 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| JAZZ | Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of … |
| ZEAL.CO | Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, … |
| ALK-B.CO | ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis … |
| ALKS | Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its … |
| MRUS | Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
ALK-Abelló
A-Score
1-Year Total Return ->
🥈
Genmab
A-Score
1-Year Total Return ->
🥉
Jazz Pharmaceuticals
A-Score
1-Year Total Return ->
4
Alkermes
A-Score
1-Year Total Return ->
5
Zealand Pharma
A-Score
1-Year Total Return ->
6
